FOR IMMEDIATE RELEASE:
1/19/2023
  • Department of Public Health
BOSTON — The Department of Public Health (DPH) today announced it has detected a novel strain of gonorrhea in a Massachusetts resident that showed reduced response to multiple antibiotics and another case with genetic markers that indicate a similar drug response. This is the first time that resistance or reduced response to five classes of antibiotics has been identified in gonorrhea in the United States.

Both cases in Massachusetts were successfully cured with ceftriaxone, the antibiotic currently recommended to treat gonorrhea. To date, no direct connection between the two individuals has been identified.

Gonorrhea is a bacterial sexually transmitted infection. It may present without symptoms, and if left untreated, can result in pelvic inflammatory disease, infertility, and other health problems.

This strain of gonorrhea has been previously seen in Asia-Pacific countries and in the United Kingdom, but not in the US. A genetic marker common to these two Massachusetts residents was also previously seen in a case in Nevada, though that strain retained sensitivity to at least one class of antibiotics. Overall, these cases are an important reminder that strains of gonorrhea in the US are becoming less responsive to a limited arsenal of antibiotics.

The Massachusetts cases were detected by DPH’s State Public Health Laboratory as part of disease surveillance activities. Field epidemiologists in DPH’s Division of Sexually Transmitted Disease Prevention are conducting contact tracing to determine if other individuals have acquired this infection. Working with the US Centers for Disease Control and Prevention (CDC) and local hospitals and health centers, DPH is expanding its testing of gonorrhea specimens for evidence of this strain in other patients.

DPH has issued an alert to clinicians and laboratories to raise awareness of this new strain. The alert recommends increased use of laboratory culture testing for individuals with symptoms of gonorrhea to detect antibiotic resistance and reminds providers of the process for submission of gonorrhea specimens to the State Public Health Laboratory to support DPH’s and CDC’s surveillance of further resistance in this organism. This alert also reinforces the CDC’s recommendation to use high doses of the antibiotic ceftriaxone for the treatment of all gonorrhea cases and to perform follow-up tests to ensure all patients with gonorrhea are successfully treated.

“The discovery of this strain of gonorrhea is a serious public health concern which DPH, the CDC, and other health departments have been vigilant about detecting in the US,” said Public Health Commissioner Margret Cooke. ...